4D Molecular Therapeutics annual net debt
2020
2021
2022
2023
2024
2025
4D Molecular Therapeutics Net Debt Growth & History (FDMT)
4D Molecular Therapeutics's net debt was −$38.8M for fiscal 2025.
View full 4D Molecular Therapeutics company overview4D Molecular Therapeutics annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$38.8M | $85.9M | — |
| 2024 | 2024-12-31 | −$124.7M | $109.7M | — |
| 2023 | 2023-12-31 | −$234.4M | −$198.2M | — |
| 2022 | 2022-12-31 | −$36.2M | $100.3M | — |
| 2021 | 2021-12-31 | −$136.6M | $140.2M | — |
| 2020 | 2020-12-31 | −$276.7M | — | — |
4D Molecular Therapeutics quarterly net debt
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$31.2M | $22.9M | — |
| Q1 2026 | 2026-03-31 | −$52.0M | $57.7M | — |
| Q4 2025 | 2025-12-31 | −$38.8M | $85.9M | — |
| Q3 2025 | 2025-09-30 | −$26.3M | $136.4M | — |
| Q2 2025 | 2025-06-30 | −$54.1M | $121.3M | — |
| Q1 2025 | 2025-03-31 | −$109.7M | $151.8M | — |
| Q4 2024 | 2024-12-31 | −$124.7M | $109.7M | — |
| Q3 2024 | 2024-09-30 | −$162.7M | $97.8M | — |
| Q2 2024 | 2024-06-30 | −$175.4M | $45.3M | — |
| Q1 2024 | 2024-03-31 | −$261.4M | −$198.5M | — |
| Q4 2023 | 2023-12-31 | −$234.4M | −$198.2M | — |
| Q3 2023 | 2023-09-30 | −$260.5M | −$168.8M | — |
| Q2 2023 | 2023-06-30 | −$220.7M | −$124.2M | — |
| Q1 2023 | 2023-03-31 | −$62.9M | −$3.7M | — |
| Q4 2022 | 2022-12-31 | −$36.2M | $100.3M | — |
| Q3 2022 | 2022-09-30 | −$91.7M | −$757,000 | — |
| Q2 2022 | 2022-06-30 | −$96.5M | $147.3M | — |
| Q1 2022 | 2022-03-31 | −$59.2M | $200.7M | — |
| Q4 2021 | 2021-12-31 | −$136.6M | $140.2M | — |
| Q3 2021 | 2021-09-30 | −$91.0M | — | — |
| Q2 2021 | 2021-06-30 | −$243.7M | — | — |
| Q1 2021 | 2021-03-31 | −$259.9M | — | — |
| Q4 2020 | 2020-12-31 | −$276.7M | — | — |
4D Molecular Therapeutics net debt trends
Over the last five fiscal years, 4D Molecular Therapeutics's net debt increased from −$276.7M to −$38.8M, a change of $237.9M. The latest reported quarter, Q2 2026, shows −$31.2M.
About the metric
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
Calculation and source
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review 4D Molecular Therapeutics source filings ↗